Abstract: Disclosed is an iontophoresis transdermal drug delivery device for cancer treatment, the device including: a power module including a battery; a microcontroller module configured to receive a voltage from the power module to output a constant-current electrical signal; and a microfluidic chip configured to store a drug and deliver the stored drug to the skin on the basis of the electrical signal.

Abstract: A soldering apparatus includes a stage on which a plurality of electronic devices are loaded, a light source disposed on the stage and configured to cast light toward the plurality of electronic devices, and a mask film disposed between the light source and the plurality of electronic devices. The mask film has openings exposing at least a portion of each of the plurality of electronic devices and a guide is connected to the mask film and extends toward the plurality of electronic devices. The guide includes a reflective material.

Abstract: The present invention provides: ferritin; a single-chain variable fragment bound to the N-terminus of the ferritin; and a fusion protein self-assembling nanoparticle structure in which an N-terminus RNA-interaction domain (RID) in a human-derived lysyl-tRNA synthetase is bound to the N-terminus of the single-chain variable fragment by means of a novel fusion partner. Therefore, the present invention provides: a fusion protein having enhanced water solubility; nanoparticles; a vector coding same; a host cell transformed by means of the vector, and a pharmaceutical composition, for treating a disease, using the same.

Abstract: A method for manufacturing a multilayer ceramic capacitor including an operation of preparing a ceramic green sheet; an operation of forming a conductive paste on the ceramic green sheet; an operation of forming a ceramic laminate by stacking a ceramic green sheet on which the conductive paste is formed; an operation of sintering the ceramic laminate; and an operation of forming an external electrode on an exterior of the ceramic laminate, wherein the conductive paste includes a first mixture including a metal powder, a dispersant, and a hydrophobic solvent and a second mixture including a hydrophilic binder and a hydrophilic solvent, the conductive paste being an emulsion in which the first mixture is dispersed in the second mixture.

Abstract: A gate driver including a plurality of stages, each of the plurality of stages including an eighth transistor connected between a third power input terminal and an output terminal, the eighth transistor including a gate electrode connected to a fourth node, a seventh transistor connected between a second power input terminal and the output terminal, the seventh transistor including a gate electrode connected to a third node, an eleventh transistor connected between the third power input terminal and the fourth node, the eleventh transistor including a gate electrode connected to a first node, a twelfth transistor connected between the first node and the third node, the twelfth transistor including a gate electrode connected to the second power input terminal, and a third capacitor connected between the third power input terminal and the fourth node.

Abstract: The present invention relates to squid-derived peptides and uses thereof and, more specifically, to uses of squid-derived peptides squidtocin and pro-sepiatocin for prevention or treatment of V1B receptor-related diseases. It has been confirmed that the squidtocin and pro-sepiatocin according to the present invention have an effect of inducing activation of a V1B receptor which is a type of vasopressin receptor. The V1B receptor which is a type of vasopressin receptor is present in the anterior pituitary and in the hippocampal CA2 region, and it is known that the V1B receptor increases intracellular calcium concentration and is involved in response to stress and sociality. Accordingly, the squidtocin and the pro-sepiatocin according to the present invention can be used in various ways in the field of prevention, amelioration, or treatment of V1B receptor-related diseases.

Abstract: Provided is a method of determining a hemostatic pressure in a tourniquet includes: driving a limb occlusion pressure (LOP) sensor, which measures a pulse signal of a subject, at a first brightness (S1); checking whether the LOP sensor and a main body are connected to each other (S2); providing a first hemostatic pressure from the main body to the tourniquet (S3); checking, on the basis of a result value of the LOP sensor, whether a pulse of the subject is detected (S4); and, when, on the basis of the result value of the LOP sensor, the pulse of the subject is determined as “not detected,” providing a hemostatic pressure, which is obtained by increasing the current hemostatic pressure by a safe hemostatic pressure, from the main body to the tourniquet (S7).